source
- Vera Therapeutics' Trutakna shows kidney function stabilization and lower death risk in Phase 3 IgAN trialVera Therapeutics reported that its drug Trutakna met its primary goals in a two‑year Phase 3 study of patients with IgA nephropathy. The therapy stabilized kidney function and lowered the risk of…
- Medicare AI prior-authorization pilot plagued by rollout glitches, causing care delaysDocuments obtained through a Freedom of Information Act lawsuit reveal that the Medicare program using artificial intelligence for prior authorization was launched hastily and suffered numerous tec…